Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

DLBCL Patients' Journey: From Symptoms to Diagnosis

Prokop Vodicka, Michal Masar, Magdalena Klanova, Katerina Benesova, Jan Koren, Pavel Klener, Petra Blahovcova, Sarka Hrabetova, Jitka Dlouha, Marek Trněný

Blood (2023) 142 (Supplement 1): 3140.

https://doi.org/10.1182/blood-2023-186207

Published: 2023

Journal Articles

Risk of Central Nervous System Vs. Systemic Relapse in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: What Should We Focus on?

Magdalena Klanova, Samuel Hricko, Michal Masar, David Salek, Prokop Vodicka, Natasa Kopalova, Petra Blahovcova, Katerina Benesova, Jozef Michalka, Jan Koren, Andrea Janikova, Marek Trneny

Blood (2023) 142 (Supplement 1): 4479.

https://doi.org/10.1182/blood-2023-178208

Published: 2023

Journal Articles

Diagnosis to Treatment Interval Is the Most Significant Prognostic Factor Compared to Symptoms to Treatment As Well As to Contact to Treatment Intervals in DLBCL Patients

Prokop Vodicka, Michal Masar, Magdalena Klanova, Katerina Benesova, Jan Koren, Pavel Klener, Petra Blahovcova, Jitka Dlouha, Sarka Hrabetova, Marek Trněný

Blood (2023) 142 (Supplement 1): 4510.

https://doi.org/10.1182/blood-2023-186467

Published: 2023

Journal Articles

Outcome of Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated with or without Rituximab

Heidi Mocikova, MD, PhD, Jozef Michalka, MD, Jan Koren, Pavla Stepankova, Alexander Wild, Ludek Raida, MD, Jana Markova, MD, Zdenek Kral, Marek Trneny, MD, Karel Indrak, MD, Prof., Jiri Mayer, M.D., PhD., Prof., Tomas Kozak, M.D., Ph.D.

Blood (2012) 120 (21): 4878.

https://doi.org/10.1182/blood.V120.21.4878.4878

Published: 2012

Journal Articles

Rapid Reduction of Light-Chains and Proteinuria in Multiple Myeloma (MM) Patients with Light Chain Induced Acute Renal Failure Treated with Lenalidomide and Dexamethasone

Heinz Ludwig, MD, Josef Thaler, Jan Koren, Ludek Pour, Ercan Müldür, Martin Schreder, MD, Niklas Zojer, Adalbert Weissmann, Zdenek Adam

Blood (2011) 118 (21): 5114.

https://doi.org/10.1182/blood.V118.21.5114.5114

Published: 2011

NARROW

DLBCL Patients' Journey: From Symptoms to Diagnosis

Risk of Central Nervous System Vs. Systemic Relapse in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: What Should We Focus on?

Diagnosis to Treatment Interval Is the Most Significant Prognostic Factor Compared to Symptoms to Treatment As Well As to Contact to Treatment Intervals in DLBCL Patients

Outcome of Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated with or without Rituximab

Rapid Reduction of Light-Chains and Proteinuria in Multiple Myeloma (MM) Patients with Light Chain Induced Acute Renal Failure Treated with Lenalidomide and Dexamethasone

Email alerts

ASH Publications

American Society of Hematology

DLBCL Patients' Journey: From Symptoms to Diagnosis

Risk of Central Nervous System Vs. Systemic Relapse in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: What Should We Focus on?

Diagnosis to Treatment Interval Is the Most Significant Prognostic Factor Compared to Symptoms to Treatment As Well As to Contact to Treatment Intervals in DLBCL Patients

Outcome of Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated with or without Rituximab

Rapid Reduction of Light-Chains and Proteinuria in Multiple Myeloma (MM) Patients with Light Chain Induced Acute Renal Failure Treated with Lenalidomide and Dexamethasone

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only